Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis

BACKGROUND: Non-small cell lung cancer (NSCLC) has a poor prognosis despite conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule tyrosine kinase inhibitors acting on epidermal growth factor receptor (EGFR) have shown high efficacy and low toxicity for NSCLC. In particul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Kenan, Zhao, Shishun, Guo, Wenlai, Ding, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220199/
https://www.ncbi.nlm.nih.gov/pubmed/32011468
http://dx.doi.org/10.1097/MD.0000000000018771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220199/
https://www.ncbi.nlm.nih.gov/pubmed/32011468
http://dx.doi.org/10.1097/MD.0000000000018771

Ejemplares similares